Global Chemotherapy Market, by Drugs (Alkylating Agents, Anti-Tumor Antibiotics, Antimetabolites, Topoisomerase Inhibitors, Mitotic Inhibitors), by Route of Drug Administration (Oral, Parenteral), by Indication (Blood Cancer, Lung Cancer, Lymphatic Cancer, Breast Cancer, Ovarian Cancer, Myeloma), End-User (Hospitals & Clinics, Research Institute) - Global Forecast Till 2026

Global Chemotherapy Market Overview

Introduction

Global chemotherapy market was valued at around USD 24,169 million in 2018 and is expected to grow with the CAGR of 5.9 % during forecast period 2019-2026.
Global Chemotherapy Market, 2016-2026 (USD Million)

Market Dynamics    
Chemotherapy is drug therapy used in the treatment of cancer. Chemotherapy prevents cancer cells from growing and it does this by killing the dividing cells. When chemotherapy drugs travel through the bloodstream to reach cells throughout the body, it is called as systemic and when drugs are directed towards a particular area of the body it is named as regional chemotherapy. It can treat various types of cancer including leukemia, breast cancer, sarcoma, lung cancer, ovarian cancer, lymphoma and many others. Despite chemotherapy is widely used treatment it has number of side effects as therapy also damages healthy cells. It shows side effects such as hair loss, nausea, vomiting, hearing impairment, fatigue, loss of appetite, mucositis and other. As per American Cancer Society statistics given for 2017, there will be an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the US.
The growing prevalence of different types of cancer, rising exposure of people to carcinogenic agents and sedentary lifestyles are the major factors driving the growth of chemotherapy market. Furthermore, the advancement in technology, surging attention to research and development in the field of oncology and government supportive programmes boost the growth of the market. Moreover, awareness among population and upgrading healthcare infrastructure is anticipated support the growth of chemotherapy market. However, unaffordable treatment cost and unfavourable reimbursement procedures in the developing countries may act as deterrent causing sluggish growth of the market.

Segment Analysis
The global chemotherapy market is segmented based on drugs, types, route of drug administration, and end-user. Based on drugs, it is segmented into alkylating agents, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and others. Alkylating agents are further segmented into alkyl sulfonates, mustard gas derivatives, ethylenimines, hydrazines and triazines, and others. Anti-tumor antibiotics are further segmented into chromomycin and anthracyclines.  Topoisomerase inhibitors are further segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors. On the basis of types, the market is segmented into blood cancer, lung cancer, lymphatic cancer, breast cancer, ovarian cancer, myeloma, and others. On the basis of route of drug administration, the market is segmented into oral and parenteral.  Based on end-user, it is segmented into hospitals& clinics, research institutes, and others.
 
Global Chemotherapy Market, By Region

Regional Analysis
Geographically, the global chemotherapy market is segmented into five major regions: North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa. The chemotherapy market in American region is enforced by upsurge in affected population, existence of key market players producing chemotherapy drugs and growing expenses on healthcare facilities. Besides, drastically changing lifestyle, high consumption of alcohol and smoking habits propels the market growth. National expenditure for cancer care in the US came up near about $ 125 billion in 2010 and could reach $ 156 billion by 2020. Europe chemotherapy market is affected by expanding number of pharmaceutical companies committed to research and government supportive activities for R&D. Asia-Pacific market is anticipated to be the fastest growing region attributed to growing geriatric population, rising demand for chemotherapy drugs, rapidly growing healthcare industry and presence of well-qualified and trained healthcare professionals such as oncologist. LAMEA is expected to witness steady growth in this market.

Key Players
Sanofi, Novartis, Eli Lilly & Company, Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceuticals Industries, Bristol-Myers Squibb, Bayer AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Boehringer Ingelheim, and others.

Recent Development
In 2019, Smart-pill maker Proteus Digital Health has launched an oral chemotherapy equipped with its ingestible sensor, which aims to help oncologists track treatment effectiveness and adherence in the cancer patients.
Additionally, AbbVie one of the leading pharmaceutical company announces US FDA approval of VENCLEXTA (venetoclax) as a chemotherapy-free combination regimen for traditionally untreated chronic lymphocytic leukemia patients.

Global Chemotherapy Market Segmentation

Global Chemotherapy Market by Type

Alkylating Agents 
Alkyl Sulfonates
Mustard Gas Derivatives
Ethylenimines
Hydrazines
Triazines
Anti-Tumor Antibiotics
Chromomycin
anthracyclines
Antimetabolites
Topoisomerase Inhibitors
Topoisomerase I inhibitors
Topoisomerase II inhibitors
Mitotic Inhibitors
Global Chemotherapy Market By Types
Blood Cancer
Lung Cancer
Lymphatic Cancer
Breast Cancer
Ovarian Cancer
Myeloma
Route of Drug Administration
Oral
Parenteral
Global Chemotherapy Market End Users
Hospitals & Clinics
Research Institutes
Others
Key Market Players
Sanofi
Novartis
Eli Lilly & Company
Pfizer Inc.
AstraZeneca
GlaxoSmithKline
Teva Pharmaceuticals Industries
Bristol-Myers Squibb
Bayer AG
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Boehringer Ingelheim